Showing results (51-60 of 62) with videos related to

Sort By:
Pageof 7
ESMO Real World Data and Digital Oncology|February 6, 2026
Observational study on the safety and effectiveness of SARS-CoV-2 vaccination in patients with lung cancerE Nadal, T Morán, A Estival, et al.
ESMO Open|December 9, 2023
Molecular profiling and feasibility using a comprehensive hybrid capture panel on a consecutive series of non-small-cell lung cancer patients from a single centreM Mosteiro, D Azuara, S Villatoro, et al.
Drug Design and Discovery|May 12, 2000
New antiherpetic 1,3-phenylene derivatives, inhibitors of the interaction of the HSV-1 origin binding protein (OBP) with DNAM Font, C Sanmartín, M L Alonso, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 30, 2017
Dual MET and ERBB inhibition overcomes intratumor plasticity in osimertinib-resistant-advanced non-small-cell lung cancer (NSCLC)A Martinez-Marti, E Felip, J Matito, et al.
Lung Cancer (Amsterdam, Netherlands)|June 16, 2019
Safety evaluation of nivolumab added concurrently to radiotherapy in a standard first line chemo-radiotherapy regimen in stage III non-small cell lung cancer-The ETOP NICOLAS trialS Peters, E Felip, U Dafni, et al.
ESMO Open|June 13, 2022
Impact of smoking status on the relative efficacy of the EGFR TKI/angiogenesis inhibitor combination therapy in advanced NSCLC-a systematic review and meta-analysisU Dafni, R A Soo, S Peters, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 25, 2020
A multicentre randomised phase III trial comparing pembrolizumab versus single-agent chemotherapy for advanced pre-treated malignant pleural mesothelioma: the European Thoracic Oncology Platform (ETOP 9-15) PROMISE-meso trialS Popat, A Curioni-Fontecedro, U Dafni, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 15, 2025
A randomised phase III study of bevacizumab and carboplatin-pemetrexed chemotherapy with or without atezolizumab as first-line treatment for advanced pleural mesothelioma: results of the ETOP 13-18 BEAT-meso trialE Felip, S Popat, U Dafni, et al.
Lung Cancer (Amsterdam, Netherlands)|July 19, 2020
Malignant pleural mesothelioma: Treatment patterns and outcomes from the Spanish Lung Cancer GroupJ Remon, E Nadal, M Dómine, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 22, 2020
Genome-wide profiling of non-smoking-related lung cancer cells reveals common RB1 rearrangements associated with histopathologic transformation in EGFR-mutant tumorsE Pros, M Saigi, D Alameda, et al.
Pageof 7